Role of erythropoietin in cancer-related anaemia: a double-edged sword? (Q37071262)

18 August 2017

1 reference

title

Role of erythropoietin in cancer-related anaemia: a double-edged sword? (English)

1 reference

18 August 2017

1 reference

X Guan

1

1 reference

18 August 2017

L Chen

series ordinal

2

1 reference

18 August 2017

publication date

1 January 2008

1 reference

Journal of International Medical Research

18 August 2017

published in

1 reference

18 August 2017

volume

36

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

1-8

1 reference

Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

The negative impact of anemia on radiotherapy and chemoradiation outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

The anaemia of cancer: death by a thousand cuts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Pharmacotherapy of anaemia in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Recombinant human erythropoietin in cancer-related anemia: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

The impact of hemoglobin levels on treatment outcomes in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1alpha oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin biology in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin receptor expression in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

The erythropoietin-receptor pathway modulates survival of cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000803600101

10.1177/147323000803600101

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference